A roster of cannabis industry heavyweights rarely assembles in a single London ballroom, yet that exact scenario unfolds November 9 at The Savoy. The Talman Group’s private investor summit convenes senior executives from Aurora, Curaleaf, Organigram, and Canopy Growth in one members-only setting.
The gathering lands amid an aggressive consolidation wave reshaping the global cannabis sector. Public company leaders weigh every word carefully, making simultaneous appearances at any event a deliberate signal rather than coincidence.
Opening the one-day program, Aurora’s Senior Vice President for UK and Europe Andreas Dotterweich will deliver the keynote address. Shortly after, Curaleaf board member Torsten Greif joins a German policy discussion. Organigram board member Max Narr, who helped engineer the Sanity Group acquisition, takes a seat on the UK panel. Meanwhile, Canopy Chief Business Development Officer Chris Gedeon closes the day with a fireside chat dissecting the company’s recent UK expansion announcement.
The room’s pulling power traces back to founder Alex Rogers. His journey began as a cannabis activist under Jack Herer in the early 1990s, later building the International Cannabis Business Conference into a European institution. Talman House represents something narrower and more exclusive. Family offices, private equity firms, venture capitalists, and top industry operators gather to evaluate deal flow directly.
Rising startups get eight minutes to pitch, followed by seven minutes of sharp questioning. No exhibition booths, no general ticket sales. Instead, deployed capital meets curated opportunity. One member with significant dry powder plans to issue a formal call for startup decks, meaning actual money enters the room looking for targets.
Beyond the marquee four, the lineup includes Michael Sassano of Somaí, Jon Robson of Mamedica, Kim Rael of Azuca, Dan Cook of True Terpenes, and global M&A broker David Hyde. Kraig Fox, former High Times CEO and current Reklaim Credit chief, will address how the US move of medical cannabis to Schedule III affects credit markets and whether UK and European banking could follow. Partners from Fieldfisher, Irwin Mitchell, and gunnercooke round out the legal perspective.
Attendees will probe what the next two years hold: who controls supply chains, who owns patient relationships, and how top-tier consolidation reshapes the industry. The real action happens after panels end, when informal networking reveals who talks to whom.
Membership remains application-based and strictly limited. The agenda is visible. The room is not.
